Market Cap (In GBp)
26.24 Million
Revenue (In GBp)
4.57 Million
Net Income (In GBp)
-8.55 Million
Avg. Volume
7683.00
- Currency
- GBp
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 62.55-185.0
- PE
- -
- EPS
- -
- Beta Value
- -0.27
- ISIN
- GB00BMWLM973
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Sarah Jennifer Howell Ph.D.
- Employee Count
- -
- Website
- https://www.arecor.com
- Ipo Date
- 2021-06-03
- Details
- Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
More Stocks
-
WVFCWVS Financial Corp.
WVFC
-
5085
-
CAGU
-
IGAR
-
QNBFBQNB Finansbank A.S.
QNBFB
-
ARYX
-
WOSSF
-
600679